文献速递胸部肿瘤

MARIPOSA长期随访:一线阿米万他单抗联合拉泽替尼对比奥希替尼对获得性耐药机制的影响

Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.
PubMed 文献 · J Thorac Oncol · 2026-04-28

MARIPOSA研究评估一线阿米万他单抗联合拉泽替尼对比奥希替尼在EGFR突变晚期NSCLC中的获得性耐药机制及其对二线PFS的影响。联合治疗组MET扩增和继发EGFR突变显著减少,二线PFS延长(8.4 vs 5.3个月;HR 0.72;名义p=0.02),提示该方案改变EGFR突变疾病的耐药生物学,贡献一线及二线长期疗效。

要点

  • 阿米万他单抗联合拉泽替尼较奥希替尼显著减少MET扩增和继发EGFR突变等耐药机制。
  • 联合治疗组二线PFS延长至8.4个月,奥希替尼组为5.3个月(HR 0.72;名义p=0.02)。
  • 治疗结束时未知耐药机制者二线PFS优于已知耐药机制者(7.4 vs 4.6个月;HR 0.63)。

核心结论

  • 阿米万他单抗联合拉泽替尼较奥希替尼减少常见获得性耐药机制(如EGFR或MET依赖),提示该方案改变EGFR突变疾病的耐药生物学,贡献一线和二线长期疗效。

研究设计与样本

  • MARIPOSA(NCT04487080)研究评估阿米万他单抗联合拉泽替尼对比奥希替尼用于既往未经治疗的EGFR突变晚期NSCLC。
  • 采用Guardant360对配对基线和治疗结束血浆ctDNA进行二代测序评估获得性耐药。

主要发现

  • MET扩增在联合组为3.4%,奥希替尼组为13.1%(名义p=0.002)。
  • 继发EGFR突变在联合组为1.4%,奥希替尼组为7.6%(名义p=0.01)。
  • 其他已知耐药通路无显著增加。
  • 阿米万他单抗治疗时间越长,获得性MET和EGFR突变越少。
  • 在开始首次后续治疗的参与者中,联合组二线PFS中位8.4个月,奥希替尼组5.3个月(HR 0.72;名义p=0.02)。

关键数值与推荐

  • 已知耐药机制包括EGFR或MET依赖(如C797S、MET扩增)及EGFR或MET非依赖(如PIK3CA、RAS或RAF、细胞周期、TP53或RB1功能缺失)。
  • 未检出上述可检测变异定义为「未知」耐药。
  • 二线PFS定义为从首次后续治疗开始至研究者评估的第二次疾病进展或死亡的时间。

临床怎么用

  • 一线阿米万他单抗联合拉泽替尼可减少EGFR或MET依赖的获得性耐药,可能延长后续治疗获益。
  • 治疗结束时ctDNA检出未知耐药者二线PFS更长,提示分子监测有助于预后分层。

局限性

  • 耐药机制基于ctDNA二代测序,可能遗漏组织水平或ctDNA未检出的耐药机制。
  • 二线PFS分析仅限开始首次后续治疗的参与者。
  • 部分比较采用名义p值,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Amivantamab plus lazertinib is approved for first-line management of EGFR-mutated advanced NSCLC. In MARIPOSA, amivantamab-lazertinib significantly improved overall survival versus osimertinib (hazard ratio [HR]: 0.75; p = 0.005). We evaluated acquired resistance mechanisms and their impact on second-line progression-free survival (PFS) in MARIPOSA. METHODS: MARIPOSA (NCT04487080) assessed amivantamab-lazertinib versus osimertinib in previously untreated EGFR-mutated advanced NSCLC. Acquired resistance was assessed by Guardant360 next-generation sequencing of circulating tumor DNA from paired baseline and end-of-treatment plasma samples. Known resistance mechanisms included EGFR- orMET-dependent (e.g., C797S, MET amplification) and EGFR- or MET-independent (e.g., PIK3CA, RASorRAF, cell cycle, TP53orRB1 loss-of-function) resistance; absence of these detectable alterations constituted "unknown" resistance. Second-line PFS was defined as time from initiation of first subsequent therapy to investigator-assessed second progressive disease or death. RESULTS: MET amplifications (3.4% versus 13.1%; nominal p = 0.002) and secondary EGFR mutations (1.4% versus 7.6%; nominal p = 0.01) were significantly reduced with amivantamab-lazertinib versus osimertinib, without significant increases in other known resistance pathways. Longer treatment with amivantamab was associated with fewer acquired MET and EGFR mutations. Median second-line PFS was substantially prolonged in the amivantamab-lazertinib versus osimertinib arm (8.4 versus 5.3 mo; HR: 0.72; nominal p = 0.02) among participants who started a first subsequent therapy. Participants harboring unknown resistance at end of treatment had longer median second-line PFS versus known resistance (7.4 versus 4.6 mo; HR: 0.63; nominal p = 0.01). CONCLUSIONS: Amivantamab-lazertinib reduces common resistance mechanisms (e.g., EGFRorMET) versus osimertinib, suggesting that this regimen is changing the underlying biology of EGFR-mutant disease, contributing to both first- and second-line long-term efficacy outcomes.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Hayashi H, Cho BC, Spigel DR, et al. Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report. J Thorac Oncol. 2026. PMID: 42061572. doi:10.1016/j.jtho.2026.103894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。